Anal Cancer Market: Global Industry Analysis and Forecast (2024-2030)

  • Anal Cancer Market size was valued at USD 698 Mn. in 2023 and the total Anal Cancer Market size is expected to grow at a CAGR of 6.4% from 2024 to 2030, reaching nearly USD 1077 Mn. by 2030.

  • Format : PDF | Report ID : SMR_2052

Anal Cancer Market Overview

Anal cancer is a form of malignancy that occurs rarely and typically initiates in the anus, which is the terminal opening of the rectum. Technological developments in targeted medicines, immunotherapies, and radiation procedures are driving a dynamic shift in the anal cancer market. Historically, the usual course of treatment has been a mix of radiation and chemotherapy, with surgery saved for special circumstances. However, immunotherapies that use the body's immune system and targeted medicines that block particular biochemical pathways are emerging as viable substitutes.


Besides this, other approaches to tumor treatment like radiation therapy involving protons and intensity-modulated radiation therapy (IMRT) are becoming better such that they can focus very effectively on tumors without causing serious side effects. Biomarker research is also gaining more interest especially when it comes to finding out who is sick at what stage and which treatments are specific for their conditions. As always, clinical trials are key when examining newly introduced management measures.


As per SMR analysis, a higher number of Anal Cancer cases were observed in localized (Stage I) anal cancer, followed by regional (Stage II–III) cases, with the fewest cases being accounted for by distant/metastatic (Stage IV) anal cancer, in the US.

Anal Cancer Market


To get more Insights: Request Free Sample Report


Anal Cancer Market Dynamics

 Drivers: Increasing Prevalence of Anal Cancer Drives the Global Market

Globally, the incidence of anal cancer has surged dramatically. The global incidence of anal cancer in 2023 was documented to be 58854 cases, as reported by GLOBOCAN. Similarly, the American Cancer Society estimates that the lifetime incidence rate of anal cancer is approximately 1 in 500. Moreover, there has been a documented rising trend in the annual incidence of mortality linked to anal cancer.


There are some people who are more likely than others to get anal cancer because they have certain things that increase their chances. Usually, squamous cell anal cancers are caused by human papillomavirus. All cancer cases across the world can be traced back to the human papillomavirus disease called HPV at about 15%. Approximately 675,500 women and 78,600 men get cancer annually due to HPV infections All these factors are driving the growth of Anal Cancer market.


Ongoing Clinical Trials and Research Creates Tremendous Opportunities

More and more clinical trials and research works are being done for anal cancer that are seeking to ascertain new drugs and treatment methods. A clinical trial began in September 2023 by Kharofa working together with Ride Cincinnati which is a non-profit bicycle organization involved in cancer research and patient treatment. The major end goal of this particular trial would be to reduce the side effects of drugs as well as improve patient outcomes especially in those ones that have been diagnosed with anal cancer, which influencing the Anal Cancer Market.


Increasing Awareness and Screening Programs:

Earlier diagnosis and better outcomes can result from raised awareness drives as well as screening activities. Likely prospects involve entering into partnerships with healthcare givers so as to encourage early detection, informing susceptible communities on preventive aspects and appealing for policy alterations that uphold screening schemes and the right to access health care. These factors fueling the growth of Anal Cancer Market.


Anal Cancer Market Segment Analysis:

Based on Treatment Type, Anal Cancer Market is Divided into Chemotherapy, Surgery, Radiation Therapy Immunotherapy However Chemotherapy treatment significantly used worldwide Chemotherapy treatment involves the use of chemical substances to kill cancer cells. Chemotherapy can be used alone or in combination with other treatments like radiation therapy and immunotherapy. Chemotherapy can cause side effects such as hair loss, nausea, and fatigue.

Anal Cancer Market1

Anal Cancer Market Regional Insights:

The North America region held the largest anal cancer market share due mainly to increased regional cases of anal cancer and significant healthcare spending. Cases of anal cancer are increasing thereby leading to increased medical attention and resources. Its well-developed healthcare infrastructure specifically in America and Canada has seen it become home for modern medical facilities as well as professionals who are able to make accurate diagnoses quickly. An increase in healthcare spending in the area has enabled the provision of intensive medical care with the most up-to-date technologies and access to experimental therapies. This is supported by raising awareness and early diagnosis through various programs, leading to better results of treatment of patients.

Anal Cancer Market2

Anal Cancer Market Competitive Landscape

  • In November 2023, Eli Lilly, an American pharmaceutical corporation, disclosed its intention to construct a new manufacturing facility in western Germany, representing a substantial investment of 2 billion euros (approximately USD 2.17 billion).
  • In August 2023, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. jointly announced that LONSURF (trifluridine/tipiracil) had been granted FDA approval for treating metastatic colorectal cancer (mCRC) in adults. This approval applies to patients who had previously received chemotherapy involving fluoropyrimidine, oxaliplatin, and irinotecan, as well as anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
  • June 2023: AstraZeneca and Daiichi Sankyo represented positive results from the clinical study of the DESTINY CRC02 phase trial for Enhertu, comprising effectiveness and safety in patients with previously treated HER-2 positive metastatic colorectal cancer.


Anal Cancer Market Scope

Anal Cancer Market

Market Size in 2023

USD 698 Mn.

Market Size in 2030

USD 1077 Mn.

CAGR (2024-2030)

6.4 %

Historic Data


Base Year


Forecast Period



By Cancer Type

  • Carcinoma In Situ
  • Squamous Cell Carcinoma
  • Melanoma
  • Adenocarcinoma
  • Basal Cell Carcinoma
  • Others

By Treatment type

  • Chemotherapy
  • Surgery
  • Radiation Therapy
  • Immunotherapy

By End User

  • Hospitals and Clinics
  • Research and Academic Institutes
  • Others

Regional Scope

North America- United States, Canada, and Mexico

Europe – United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe

Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC

Middle East and Africa - South Africa, GCC, Egypt, Rest of the Middle East and Africa

South America – Brazil, Argentina, Rest of South America


Anal Cancer Market Key Players

  • Novartis AG
  • Sanofi
  • AstraZeneca plc
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Advaxis Inc.
  • Spectrum Pharmaceuticals, Inc
  • Merck
  • Bayer AG
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Atara Biotherapeutics Inc.
  • Amgen Inc.
  • Isofol
  • Tanvex Biopharma
  • Sebela Pharmaceuticals
  • Leap Therapeutics
  • XX Inc

Frequently Asked Questions

Increasing Prevalence of Anal Cancer Drives the Global Market, Ongoing Trails and research developments are the growth drivers for the Anal Cancer Market.

1.    Anal Cancer Market: Research Methodology 
2.    Anal Cancer Market: Executive Summary
3.    Anal Cancer Market: Competitive Landscape
4.    Potential Areas for Investment

4.1. Stellar Competition Matrix
4.2. Competitive Landscape
4.3. Key Players Benchmarking
4.4. Market Structure
4.4.1.    Market Leaders 
4.4.2.    Market Followers
4.4.3.    Emerging Players

4.5. Consolidation of the Market
5.    Anal Cancer Market Import Export Landscape
5.1. Import Trends
5.2. Export Trends
5.3. Regulatory Compliance
5.4. Major Export Destinations
5.5. Import-Export Disparities
6.    Anal Cancer Market: Dynamics
6.1. Market Trends by Region
6.1.1.    North America
6.1.2.    Europe
6.1.3.    Asia Pacific
6.1.4.    Middle East and Africa
6.1.5.    South America

6.2. Market Drivers by Region
6.2.1.    North America
6.2.2.    Europe
6.2.3.    Asia Pacific
6.2.4.    Middle East and Africa
6.2.5.    South America

6.3. Market Restraints
6.4. Market Opportunities
6.5. Market Challenges
6.6. PORTER’s Five Forces Analysis
6.7. PESTLE Analysis
6.8. Strategies for New Entrants to Penetrate the Market
6.9. Regulatory Landscape by Region
6.9.1.    North America
6.9.2.    Europe
6.9.3.    Asia Pacific
6.9.4.    Middle East and Africa
6.9.5.    South America

7.    Anal Cancer Market Size and Forecast by Segments (by Value Units)
7.1. Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
7.1.1.    Carcinoma In Situ
7.1.2.    Squamous Cell Carcinoma
7.1.3.    Melanoma
7.1.4.    Adenocarcinoma
7.1.5.    Basal Cell Carcinoma
7.1.6.    Others 

7.2. Anal Cancer Market Size and Forecast, by Treatment Type (2023-2030)
7.2.1.    Chemotherapy
7.2.2.    Surgery
7.2.3.    Radiation Therapy
7.2.4.    Immunotherapy 

7.3. Anal Cancer Market Size and Forecast, by End User (2023-2030)
7.3.1.    Hospitals and Clinics
7.3.2.    Research and Academic Institutes
7.3.3.    Others 

7.4. Anal Cancer Market Size and Forecast, by Region (2023-2030)
7.4.1.    North America
7.4.2.    Europe
7.4.3.    Asia Pacific
7.4.4.    Middle East and Africa
7.4.5.    South America

8.    North America Anal Cancer Market Size and Forecast (by Value Units)
8.1. North America Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
8.1.1.    Carcinoma In Situ
8.1.2.    Squamous Cell Carcinoma
8.1.3.    Melanoma
8.1.4.    Adenocarcinoma
8.1.5.    Basal Cell Carcinoma
8.1.6.    Others

8.2. Anal Cancer Market Size and Forecast, by Treatment Type (2023-2030)
8.2.1.    Chemotherapy
8.2.2.    Surgery
8.2.3.    Radiation Therapy
8.2.4.    Immunotherapy 

8.3. Anal Cancer Market Size and Forecast, by End User (2023-2030)
8.3.1.    Hospitals and Clinics
8.3.2.    Research and Academic Institutes
8.3.3.    Others 

8.4. North America Anal Cancer Market Size and Forecast, by Country (2023-2030)
8.4.1.    United States
8.4.2.    Canada
8.4.3.    Mexico

9.    Europe Anal Cancer Market Size and Forecast (by Value Units)
9.1. Europe Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
9.1.1.    Carcinoma In Situ
9.1.2.    Squamous Cell Carcinoma
9.1.3.    Melanoma
9.1.4.    Adenocarcinoma
9.1.5.    Basal Cell Carcinoma
9.1.6.    Others

9.2. Anal Cancer Market Size and Forecast, by Treatment Type (2023-2030)
9.2.1.    Chemotherapy
9.2.2.    Surgery
9.2.3.    Radiation Therapy
9.2.4.    Immunotherapy

9.3. Anal Cancer Market Size and Forecast, by End User (2023-2030)
9.3.1.    Hospitals and Clinics
9.3.2.    Research and Academic Institutes
9.3.3.    Others 

9.4. Europe Anal Cancer Market Size and Forecast, by Country (2023-2030)
9.4.1.    UK
9.4.2.    France
9.4.3.    Germany
9.4.4.    Italy
9.4.5.    Spain
9.4.6.    Sweden
9.4.7.    Russia 
9.4.8.    Rest of Europe

10.    Asia Pacific Anal Cancer Market Size and Forecast (by Value Units)
10.1. Asia Pacific Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
10.1.1.    Carcinoma In Situ
10.1.2.    Squamous Cell Carcinoma
10.1.3.    Melanoma
10.1.4.    Adenocarcinoma
10.1.5.    Basal Cell Carcinoma
10.1.6.    Others

10.2. Anal Cancer Market Size and Forecast, by Treatment Type (2023-2030)
10.2.1.    Chemotherapy
10.2.2.    Surgery
10.2.3.    Radiation Therapy
10.2.4.    Immunotherapy

10.3. Anal Cancer Market Size and Forecast, by End User (2023-2030)
10.3.1.    Hospitals and Clinics
10.3.2.    Research and Academic Institutes
10.3.3.    Others 

10.4. Asia Pacific Air Traffic Control (ATC) Communications Market Size and Forecast, by Country (2023-2030)
10.4.1.    China
10.4.2.    S Korea
10.4.3.    Japan
10.4.4.    India
10.4.5.    Australia
10.4.6.    Indonesia 
10.4.7.    Malaysia
10.4.8.    Vietnam
10.4.9.    Taiwan
10.4.10.    Bangladesh
10.4.11.    Pakistan
10.4.12.    Rest of Asia Pacific

11.    Middle East and Africa Anal Cancer Market Size and Forecast (by Value Units)
11.1. Middle East and Africa Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
11.1.1.    Carcinoma In Situ
11.1.2.    Squamous Cell Carcinoma
11.1.3.    Melanoma
11.1.4.    Adenocarcinoma
11.1.5.    Basal Cell Carcinoma
11.1.6.    Others 

11.2. Middle East and Africa Market Size and Forecast, by Treatment Type (2023-2030)
11.2.1.    Chemotherapy
11.2.2.    Surgery
11.2.3.    Radiation Therapy
11.2.4.    Immunotherapy

11.3. Anal Cancer Market Size and Forecast, by End User (2023-2030)
11.3.1.    Hospitals and Clinics
11.3.2.    Research and Academic Institutes
11.3.3.    Others

11.4. Middle East and Africa Anal Cancer Market Size and Forecast, by Country (2023-2030)
11.4.1.    South Africa
11.4.2.    GCC
11.4.3.    Egypt
11.4.4.    Nigeria
11.4.5.    Rest of ME&A

12.    South America Anal Cancer Market Size and Forecast (by Value Units)
12.1. South America Anal Cancer Market Size and Forecast, by Cancer Type (2023-2030)
12.1.1.    Carcinoma In Situ
12.1.2.    Squamous Cell Carcinoma
12.1.3.    Melanoma
12.1.4.    Adenocarcinoma
12.1.5.    Basal Cell Carcinoma
12.1.6.    Others 

12.2. South America Market Size and Forecast, by Treatment Type (2023-2030)
12.2.1.    Chemotherapy
12.2.2.    Surgery
12.2.3.    Radiation Therapy
12.2.4.    Immunotherapy 

12.3. Anal Cancer Market Size and Forecast, by End User (2023-2030)
12.3.1.    Hospitals and Clinics
12.3.2.    Research and Academic Institutes
12.3.3.    Others

12.4. South America Anal Cancer Market Size and Forecast, by Country (2023-2030)
12.4.1.    Brazil
12.4.2.    Argentina
12.4.3.    Rest of South America

13.    Company Profile: Key players
13.1.1.    Novartis AG    Company Overview    Financial Overview    Business Portfolio    SWOT Analysis    Business Strategy    Recent Developments

13.2. Sanofi
13.3. AstraZeneca plc
13.4. Johnson & Johnson
13.5. GlaxoSmithKline plc
13.6. Pfizer Inc.
13.7. Advaxis Inc.
13.8. Spectrum Pharmaceuticals, Inc
13.9. Merck
13.10. Bayer AG
13.11. Bristol-Myers Squibb Company
13.12. AbbVie Inc.
13.13. F. Hoffmann-La Roche Ltd.
13.14. Eli Lilly and Company
13.15. Atara Biotherapeutics Inc.
13.16. Amgen Inc.
13.17. Isofol
13.18. Tanvex Biopharma
13.19. Sebela Pharmaceuticals
13.20. Leap Therapeutics
13.21. XX Inc 
14.    Key Findings
15.    Industry Recommendation

Enquiry Before Buy

Request Sample PDF